Warhound Aims to Field Genetically Enhanced Military Dogs

The project represents a partnership between Colossal Biosciences co-founder Ben Lamm and defense entrepreneur Palmer Luckey. While Luckey helped conceive the startup, he holds no equity or formal role in the entity. Former intelligence specialist and Marine veteran David Spirk has been appointed CEO, tasked with guiding the company toward a primary objective: reducing the current reliance on foreign-sourced animals. Today, roughly 80 percent of US military dogs are imported from Europe, yet less than half meet the rigorous standards required for service after a three-year training cycle.

Colossal plans to utilize CRISPR and other genetic tools to eliminate hereditary health issues like poor vision or cancer susceptibility in breeds such as the Belgian Malinois and German Shepherd. Beyond health, the company aims to augment physical traits, specifically targeting speed, agility, and olfactory sensitivity for explosive detection. Once bred, these animals will be equipped with Anduril’s EagleEye technology and specialized cybernetic gear. This integration is designed to provide both the canine and its handler with superior situational awareness in dangerous environments. The American Humane Society is slated to oversee the company's training programs and ethical standards as it develops this new category of specialized working animals.